Duke Clinical Research Institute (DCRI), an prestigious research organization, recently selected a mid-market contract research organization (CRO) out of Sweden called TFS to provide data management solutions across the academic research organizations’ study profile. According to a recent press release, the partnership supports TFS’s growth strategy and aligns with its clinical development services with an organization (DCRI) renowned for bringing innovation to clinical trial design and execution. A unique collaboration brings together TFS’ capability to execute clinical trials for sponsors. Apparently, the Nordic CRO has been working with DCRI for several years now, adding value along the way, hence the bigger contract.
Who is TFS?
Founded in 1996, this mid-sized yet global CRO has emphasized small to mid-sized life science clients. Now employing over 700 professionals throughout 21 countries, the company is delivering clinical research services in more than 40 countries. The company is led by Dr. Bassem Saleh, experienced Hemato-Oncologist and Pharmaceutical Medicine Consultant, with more than 12 years’ experience in drug development.
Based on a preliminary and high level TrialSite review, TFS is known for its four principles, including 1), commitment 2) flexibility, 3) value creation, and 4) global reach. The firm emphasizes a handful of important therapeutic domains, including Oncology, Immunology, Dermatology, Ophthalmology, CNS, Cardiology and Endocrinology.
TrialSIte’s founder, Daniel O’Connor, suggested that DCRI is one of the world’s most innovative academic research organizations sharing “TFS is impressing the clinical research market with deals like this.”
The company is headquartered in Lund with a U.S. base in Princeton, NJ.
Call to Action: TrialSite suggests small and mid-sized sponsors take a look at TFS.